Soligenix, Inc. (LON:0A6I)
1.240
-0.010 (-0.80%)
At close: Feb 3, 2026
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-554.06K GBP
Market Cap
9.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | 18 | 2 | 12.50% | 17 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Asia Strategic Holdings | 2,530 |
| Caffyns | 455 |
| Nanoco Group | 38 |
| Genflow Biosciences | 5 |
| Mila Resources | 5 |
Soligenix News
- 6 weeks ago - Soligenix (SNGX) Shows Promising Results in Phase 2a Behcet's Disease Study - GuruFocus
- 6 weeks ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 6 weeks ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 6 weeks ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 6 weeks ago - Soligenix (SNGX) Reports Promising Phase 2a Results for Psoriasis Treatment - GuruFocus
- 6 weeks ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 2 months ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 2 months ago - Soligenix (SNGX) Completes Key Enrollment for Phase 3 Study on CTCL Treatment - GuruFocus